Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
NCT00195286
Last updated date
ABOUT THIS STUDY
The primary objective is to study the efficacy of piperacillin/tazobactam in patients with
complicated urinary tract infections
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Urinary Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
16 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Patients known, or thought to be hypersensitivity to beta-lactams
- Patients with an uncomplicated urinary tract infection
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Urinary InfectionsStudy Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
NCT00195286
- Antequera (Málaga),
- Avila,
- Barcelona,
- Berga (Barcelona),
- Caceres,
- Castellón,
- Ciudad Real,
- Cuenca,
- Cádiz,
- Ferrol,
- Granada,
- Jaen,
- Las Palmas,
- Lorca (Murcia),
- Lugo,
- Lérida,
- Madrid,
- Osuna (Sevilla),
- Palma Mallorca,
- Pamplona,
- Pontevedra,
- Terrasa,
- Torrelavega,
- Valencia,
- Valladolid,
- Vitoria,
- Zaragoza,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections. | |||
| Official Title | Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections. | |||
| Brief Summary | The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections | |||
| Detailed Description | Not Provided | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Case-Only Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | Patients treated at internal medicine units | |||
| Condition | Urinary Infections | |||
| Intervention | Drug: piperacillin/tazobactam | |||
| Study Groups/Cohorts | Not Provided | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 180 | |||
| Original Enrollment | 300 | |||
| Actual Study Completion Date | July 2007 | |||
| Actual Primary Completion Date | July 2007 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 16 Years and older (Child, Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Spain | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00195286 | |||
| Other Study ID Numbers | 101315 | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth | |||
| Study Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Verification Date | September 2009 | |||